Precigen (PGEN) is back in focus after confirming a presentation slot at the 2026 Cell & Gene Meeting on the Mediterranean on April 29, highlighting its transition into a commercial rare disease platform.

The stock has been active around the Papzimeous launch story, with a 1 day share price return of 4.59%, a 30 day share price return of 9.90%, and a 1 year total shareholder return above 200%, although the 90 day share price return shows some loss of momentum.

If you are looking beyond Precigen for other potential opportunities in high growth areas, this is a good moment to check out 35 healthcare AI stocks.

With Papzimeous now approved and Precigen shifting into commercial mode, the stock sits around $4.33 against an analyst price target of $9.50. This raises the question: is this a genuine discount, or is the market already pricing in future growth?

Most Popular Narrative: 49.1% Undervalued

Precigen's most followed narrative pegs fair value at $8.50 per share, compared with the latest close at $4.33. This sets up a wide valuation gap for investors to assess.

Expanding indications, including the planned pediatric RRP trial and geographic expansion via the EMA marketing authorization application, create additional addressable markets that can extend the revenue growth curve and leverage existing commercial infrastructure.

Want to understand why this narrative backs such a large upside gap? It focuses on rapid revenue build, margin expansion, and a richer earnings multiple. Curious how those moving parts interact to support that $8.50 figure, and what would need to go right to get there?

Result: Fair Value of $8.50 (UNDERVALUED)

However, this upside story can break if PAPZIMEOS uptake lags expectations or if future financing materially dilutes existing shareholders.

Another Angle on Value

The narrative fair value of $8.50 suggests upside, but the price tag looks very different when looking at P/B. Precigen trades at 73.3x P/B versus 2.3x for the US Biotechs industry and 15.4x for peers, which points to a rich valuation and raises the risk that expectations are doing a lot of the heavy lifting. Are you comfortable paying that kind of premium for this story?

Next Steps

With sentiment clearly split between upside potential and real concerns, this is a good time to study the numbers yourself and move quickly to shape your own view. You can start with 2 key rewards and 3 important warning signs.

Ready to find your next idea?

If Precigen has caught your attention, do not stop here. Broaden your watchlist now so you are not relying on a single story.

• Target potential mispricings by scanning a curated list of companies that may trade below their fundamentals with the 51 high quality undervalued stocks.
• Prioritize resilience by searching for stocks that pair lower risk profiles with steady fundamentals using the 72 resilient stocks with low risk scores.
• Hunt for underfollowed opportunities by checking the screener containing 25 high quality undiscovered gems that combine quality metrics with fewer eyes on them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.